Clinical Research Directory

Inclusion Criteria: * Patients with a typical or atypical hypertrophic cardiomyopathy (HCM) confirmed by imaging modalities (echo and MRI) and/or genetic tests or a relative history of HCM * Left ventricular obstruction during exercise on treadmill (above 50 mmHg) * Positive response to leg lifting test (obstruction reduction above 20 mmHg) at rest or in early recovery phase * Daily symptoms as shortness of breath during exercise (NYHA2-3), non coronary chest pain, dizziness * Correct ultrasound windows quality * Sinus rhythm * Optimal medical treatment * For women, pregnancy test or contraception * Written consent form obtained Exclusion Criteria: * Previous treatment by BX1514M * Extra-cardiac pathology with life expectancy below than 1 year * No capability of consent form written * Pregnancy women * Secondary hypertension hypertrophy, secondary valvular disease hypertrophy * Permanent atrial fibrillation * Severe ventricular arrhythmia without Implantable Cardioverter Defibrillator (ICD) * Severe coronary disease * Severe non stabilized hypertension * Severe cardiopathy (ejection fraction below 40% or demonstrated elevated end diastolic pressure or pulmonary pressure above 60 mmHg) * Bradycardia * Narrow angle glaucoma * Vascular prethrombotic diseases * Vascular spams * Thyrotoxicosis * Pheochromocytoma * Severe renal failure (\<30ml/mn) * Patients at risk of urinary retention secondary to prostatic severe disease * Raynaud's disease * Non selective Monoamine Oxidase Inhibitors (MAOIs), iproniazid, nialamide or ephedrine, methylphenidate, phenylephrine, pseudoephedrine or digitalic * Procedures modifying the peripheral venous return * Participation to other research protocol